Related Experiment Video
Updated: Jan 11, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Promising Effects of CAR T-Cell Therapy in Refractory Stiff Person Syndrome and a Hopeful Future for All
1Thomas Jefferson University, Philadelphia, PA; and.
Abstract:
Chimeric antigen receptor (CAR) T cells are genetically modified T cells expressing CARs, initially developed to recognize tumor antigens and kill cancer cells that evade T-cell recognition. Because of their impressive success in hemato-oncologic malignancies, CAR T cells are being repurposed with redesigned constructs for safety and sustained efficacy to target refractory systemic autoimmune or neurologic diseases. The CD19 CAR T cells-targeting those CD19-positive, antibody-secreting, long-lived plasma cells, and plasmablasts-are now extensively explored in refractory neuroautoimmunities with promising benefits based on case series in patients with myasthenia gravis (MG), stiff person syndrome (SPS), neuromyelitis, myositis, and multiple sclerosis; some patients with MG and SPS with steadily progressive and disabling disease refractory to all available therapies, including rituximab and new biologics, exhibit impressive clinical improvements with long-lasting benefits. The review, triggered by these early results and ongoing trials, addresses what these cells are and why they show effectiveness not only in antibody-mediated B-cell neurologic diseases unresponsive to available anti-B-cell agents but also in patients with nonpathogenic antibodies, implying effects even beyond B cells; points out that CARs are "living cells" penetrating physiologic barriers, such as the blood-brain barrier, expanding within tissues to memory cells ensuring sustained effects; describes the process and challenges of preparing and administering CAR T cells and their safety profile stressing the differences in toxicities when treating autoimmunites vs malignancies; and highlights that CD19 CAR T cells can successfully target even 2 different autoimmune diseases in the same patient, such as SPS and MG, offering promising prospects of changing the therapeutic algorithm in all neuroautoimmunities with potential for achieving even an immune reset shifting immunity to a healthy state.
Insights
Chimeric antigen receptor (CAR) T-cell therapy shows promise for autoimmune neurological diseases. These engineered T-cells target CD19-positive cells, offering sustained benefits for conditions like myasthenia gravis and stiff person syndrome.
Area of Science:
- Immunology
- Neurology
- Cell Therapy
Background:
- CAR T-cells, initially for cancer, are repurposed for autoimmune diseases.
- CD19 CAR T-cells target CD19-positive plasma cells and B cells implicated in autoimmunity.
- Success in hemato-oncologic malignancies drives exploration in refractory neuroautoimmune conditions.
Purpose of the Study:
- To review the mechanism, efficacy, and safety of CAR T-cells in neuroautoimmune diseases.
- To explore CAR T-cell effectiveness beyond B-cell targeting.
- To highlight the potential of CAR T-cells in refractory autoimmune neurological disorders.
Main Methods:
- Review of case series and ongoing trials involving CD19 CAR T-cell therapy.
- Analysis of CAR T-cell properties, including tissue penetration and expansion.
- Comparison of CAR T-cell toxicities in autoimmune diseases versus malignancies.
Main Results:
- CD19 CAR T-cells demonstrate promising clinical improvements and long-lasting benefits in patients with myasthenia gravis and stiff person syndrome.
- Effectiveness is observed in antibody-mediated diseases unresponsive to other therapies, and potentially in nonpathogenic antibody conditions.
- CAR T-cells can penetrate the blood-brain barrier and expand in tissues, ensuring sustained therapeutic effects.
- Simultaneous targeting of multiple autoimmune diseases, like SPS and MG, is feasible with CD19 CAR T-cells.
Conclusions:
- CD19 CAR T-cell therapy offers a promising new therapeutic approach for refractory neuroautoimmune diseases.
- This therapy has the potential to induce an immune reset, shifting the immune system to a healthy state.
- CAR T-cells represent a significant advancement in the treatment of complex autoimmune neurological conditions.
Related Concept Videos
Tumor Immunotherapy
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...

